Search

Glaukos Corp

Cerrado

SectorSanidad

245.53 -0.15

Resumen

Variación precio

24h

Actual

Mínimo

244.51

Máximo

248.8

Métricas clave

By Trading Economics

Ingresos

20M

2M

Ventas

25M

211M

BPA

0.47

Margen de beneficios

0.956

Empleados

1,094

EBITDA

18M

12M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

-3.22% downside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

3.6B

14B

Apertura anterior

245.68

Cierre anterior

245.53

Glaukos Corp Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

13 nov 2026, 21:07 UTC

Glaukos Corporation is roughly flat as the broader market declines, amid October PPI data that may impact Federal Reserve interest rate decisions.

11 nov 2026, 21:01 UTC

Glaukos Corporation shares are advancing with unusually high trading volume.

9 nov 2026, 21:03 UTC

Social Media

Glaukos Corporation shares rose sharply on Monday after a surprise positive earnings per share announcement, with unusually high trading volume reported.

6 nov 2026, 21:02 UTC

Glaukos Corporation is seeing higher trading activity with unusually high volume, peaking earlier in the day while remaining above its 20-day moving average.

5 nov 2026, 21:03 UTC

Glaukos Corporation shares fell sharply after a brief uptick, trading with unusually high volume while remaining above its 20-day moving average.

4 nov 2026, 21:02 UTC

Glaukos Corporation shares are advancing, supported by strong trading volume, despite earlier pulling back from a session high. The health care equipment sector shows positive momentum.

3 nov 2026, 20:51 UTC

Glaukos Corporation shares are declining, retracing from an earlier peak, despite remaining significantly above Monday's close amid unusually high trading volume.

2 nov 2026, 20:56 UTC

News
Social Media

Glaukos Corporation will be added to the S&P MidCap 400 index, a development that may enhance its visibility among investors.

30 oct 2026, 19:42 UTC

Social Media

Glaukos Corporation shares fell amid a broader market downturn, with unusually high trading volume today.

29 oct 2026, 20:03 UTC

Social Media
News

Stock advances after return to profitability, $2 million net income.

28 oct 2026, 23:02 UTC

Social Media
News

Glaukos Corporation reported record Q3 net sales of $211 million and raised its 2026 sales guidance to between $775 million and $785 million.

27 oct 2026, 20:01 UTC

Glaukos Corporation shares are experiencing higher trading activity today, reaching a notable peak earlier in the session before pulling back slightly.

26 oct 2026, 23:46 UTC

Glaukos Corp shares are trading higher in after-market hours, remaining near the upper end of their one-month trading range.

22 oct 2026, 20:07 UTC

Glaukos Corp shares are declining, retracing from an early session peak to approach the day's low amid a slight overall market decline.

21 oct 2026, 20:07 UTC

Glaukos Corp shares advanced throughout Wednesday, peaking in the afternoon before a slight pullback, remaining above their 20-day moving average.

20 oct 2026, 20:01 UTC

Glaukos Corp shares are significantly higher, currently 7.32% above their 20-day moving average and near the upper end of their one-month range.

16 oct 2026, 19:36 UTC

Glaukos Corp shares fell sharply, marking a notable decline since Thursday's close and currently positioned around the midpoint of its one-month trading range.

15 oct 2026, 20:07 UTC

Glaukos Corp shares are declining, reversing an early spike to finish lower from Wednesday's close amid unusual volatility.

13 oct 2026, 20:07 UTC

Glaukos Corp shares are declining, following a volatile intraday pattern, closing lower from Monday's close despite briefly recovering earlier in the session.

9 oct 2026, 20:06 UTC

News
Event

Glaukos reports positive Phase 4 trial results for iDose TR therapy, showing a significant reduction in intraocular pressure alongside cataract surgery, confirming safety.

8 oct 2026, 22:55 UTC

Glaukos Corp shares declined in after-market hours, continuing a downward trend from Thursday's close and remaining below its 20-day moving average.

7 oct 2026, 20:00 UTC

Glaukos Corp is advancing significantly with unusually high trading volume, marking a departure from recent higher daily closes since Tuesday.

6 oct 2026, 20:07 UTC

Glaukos Corp shares are declining, trading below their 20-day moving average and near the lower end of their one-month range after earlier volatility.

1 oct 2026, 20:07 UTC

Glaukos Corp's shares are declining, positioned near the lower end of their one-month range, after a brief spike earlier in the session.

30 sept 2026, 20:07 UTC

Glaukos Corp shares are advancing, rebounding from an earlier pullback, amid a broader market trend of significant gains on Wednesday.

29 sept 2026, 23:55 UTC

Glaukos Corp is trading modestly higher in after-market hours, despite fluctuations during the session, and remains below its 20-day moving average.

28 sept 2026, 20:07 UTC

Glaukos Corp is gaining ground in today's trading session, reflecting upward momentum since Friday, despite earlier pulling back from a session high.

25 sept 2026, 20:07 UTC

Glaukos Corp shares fell sharply, closing just below Thursday's close and approximately 9.45% below their 20-day moving average.

23 sept 2026, 20:01 UTC

News

Glaukos Corporation launched a keratoconus awareness campaign with Stephen Curry, but shares fell sharply today, continuing a trend of three consecutive daily declines.

22 sept 2026, 23:01 UTC

Glaukos Corp is advancing in after-market trading, reflecting a directional move since Tuesday's close, though it remains 6.99% below its 20-day moving average.

Comparación entre iguales

Cambio de precio

Glaukos Corp previsión

Precio Objetivo

By TipRanks

-3.22% descenso

Estimación a 12 Meses

Media 237.818 USD  -3.22%

Máximo 255 USD

Mínimo 210 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Glaukos Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

11 ratings

10

Comprar

1

Mantener

0

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Glaukos Corp

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
help-icon Live chat